This Article Full Text Full Text (PDF) Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Google Scholar Articles by Newcomer, L. PubMed Articles by Newcomer, L. Social Bookmarking                            What's this?

Three Changes for Affordable Care: One Payer's Wish List

UnitedHealth Group, Edina, MN

Corresponding author: Lee Newcomer, MD,UnitedHealthcare, 9900 East Bren Rd, Minnetonka, MN 55343; lee_newcomer@uhc.com

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Any oncologist's first reaction to the issue of cost is likely to be: "Haven't I heard all of this before, and haven't we always found a way to fund more care? What is different this time?" Ever since the discovery of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy, payers have paid oncologists directly for cancer chemotherapy.

This time, we have reached a tipping point. When MOPP was discovered in the 1970s, a minimum-wage worker in California could provide coverage for his or her family of four with a standard Blue Cross/Blue Shield health plan for 15% of his or her . . . [Click for More]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?